Does omega-3 supplementation reduce cardiovascular mortality?

What the strongest evidence shows: a modest but real benefit for cardiovascular death

The most comprehensive analysis available—a 2021 meta-analysis of 38 randomized controlled trials with over 149,000 participants—found that omega-3 fatty acid supplementation reduced cardiovascular mortality by 7% (risk ratio 0.93, 95% CI 0.88–0.98) [5]. This means that for every 1,000 people treated, roughly 7 fewer would die from a heart-related cause over the study period. The same analysis also found reductions in non-fatal heart attacks (13% lower risk) and major adverse cardiovascular events (5% lower risk) [5]. Importantly, the benefit was more pronounced with pure EPA (eicosapentaenoic acid) supplements than with combined EPA and DHA (docosahexaenoic acid) [5].

A separate 2022 meta-analysis of 14 large trials (over 135,000 people) confirmed a 6% reduction in cardiovascular death and a 14% reduction in heart attacks, with the sweet spot for dosing being 0.8–1.2 grams per day [1]. These two large meta-analyses, which together cover most of the major trials, converge on the same conclusion: omega-3s provide a small but statistically significant benefit for cardiovascular mortality.

Who benefits most? The gap between best-case and typical-case evidence

The benefit is not uniform. The strongest effects are seen in people who already have cardiovascular disease or are at very high risk. For example, a 2026 meta-analysis of hemodialysis patients—a group with extremely high cardiovascular risk—found a 45% reduction in cardiovascular death (risk ratio 0.55, 95% CI 0.42–0.71) [2]. Similarly, a 2025 study of people with established cardiovascular disease found that those with the highest dietary omega-3 intake had a 37% lower risk of dying from heart disease (hazard ratio 0.63, 95% CI 0.42–0.95) [6]. In contrast, for healthy people without heart disease, the evidence is weaker. A large 2024 UK Biobank study found that regular fish oil use was actually associated with a 13% higher risk of developing atrial fibrillation (a heart rhythm disorder) and a 5% higher risk of stroke in people who were initially healthy [3]. This suggests that for primary prevention, the risk-benefit balance may be different.

The type of omega-3 also matters. The 2021 meta-analysis found that pure EPA supplements reduced cardiovascular mortality by 18% (risk ratio 0.82), whereas combined EPA+DHA only reduced it by 6% (risk ratio 0.94) [5]. High-dose prescription EPA (icosapent ethyl, 4 grams daily) is recommended by guidelines for secondary prevention in patients with high triglycerides who are already on statins [8]. However, over-the-counter fish oil supplements (which are typically lower-dose EPA+DHA combinations) have not shown the same benefit in contemporary trials where patients are on optimal statin therapy [7][8].

Does omega-3 reduce overall death risk? The answer is less clear

While omega-3s reduce cardiovascular death, they do not consistently reduce all-cause mortality (death from any cause). The 2022 meta-analysis of 14 trials found no significant effect on all-cause death [1]. Similarly, the hemodialysis meta-analysis found a non-significant 7% reduction in all-cause mortality [2]. This pattern suggests that omega-3s may prevent some heart-related deaths but not enough to shift the overall death rate, possibly because other causes of death (cancer, accidents, etc.) are unaffected. However, a 2024 study of osteoarthritis patients found a 49% reduction in all-cause mortality with higher omega-3 intake [4], and a 2025 study of cardiovascular disease patients found a 23% reduction [6]. These observational studies may reflect the benefits of a healthy diet overall, not just the supplement.

Omega-3s also increase the risk of atrial fibrillation by about 26% (risk ratio 1.26) [5], and pure EPA may increase bleeding risk by 49% [5]. These side effects are important to weigh against the modest cardiovascular benefits, especially for people who are otherwise healthy.

About These Sources

This answer is built on 8 peer-reviewed studies — published from 2021 to 2026, 4 from 2024 or later, 7 in Q1 journals, collectively cited 453 times — selected as the most relevant from 13 studies that passed quality screening, drawn from 51 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions